[The endothelial dysfunction in patients with arterial hypertension after old hemorrhagic stroke.]

G Kh Mirsaeva1, R A Khakimova1

  • 1The Federal state budget educational institution of higher education "The Bashkir state medical university" of Minzdrav of Russia, 450005, Ufa, Russia.

The higher risk of development of cerebral complications in patients with arterial hypertension is related to formation of dysfunction of endothelium preventing appropriate regulation of cerebral bloodstream. The decreasing of athrombogenic characteristics of vessel wall can results in increased adhesion of thrombocytes on endothelium of wall of vessels, activation of hemostasis system and thrombosis. The purpose of the study is to establish the level of markers of dysfunction of endothelium-von Willebrand factor and tissue activator plasminogen in patients with arterial hypertension in dynamics after old hemorrhagic stroke. The sampling of examined patients consisted of 82 persons (main group) with arterial hypertension in various periods after old hemorrhagic stroke. To evaluate condition of endothelium activity of von Willebrand factor was detected using the technique of ristocetin-cofactor activity applying the reagents' set by Dade Behring (Germany). Also, the level of antigen and indicator of activity of tissue activator plasminogen was detected using immune enzyme technique ELISA Actibind t-PA applying reagents' set Technoclone (Austria). The statistical data processing was implemented by integrated software Statistica 8 for Windows (StatSoft). In patients with arterial hypertension independently of period of hemorrhagic stroke an endothelial dysfunction is detected presented by decreasing of level of tissue plasminogen activator and increasing of its activity. The increasing of activity of von Willebrand factor was established only in patients at early rehabilitation period of hemorrhagic stroke that indicates the stablecharacter of endothelial dysfunction in the given category of patients. The established disorders related to pathology of vessel wall can be characterized as prothrombotic that is a prognostically unfavorable factor and substantiates necessity of medicinal correction of detected disorders.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
594
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
464
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
493
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
611
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
506
Hypertension I: Introduction01:28

Hypertension I: Introduction

Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
843